Background: Due to the mechanism of action of the dopamine transporter (DAT) in drug addiction, the DAT1 gene is a potential candidate for molecular studies. This paper aims to compare the prevalence of allele and genotype frequencies created by the 3′ UTR variable number of tandem repeats (VNTR) of this gene between crack cocaine users and controls. Methods: A cross-sectional sample of 237 current adult crack cocaine abusers or dependents (DSM-IV TR criteria) from in- and outpatient clinics in southern Brazil and 205 community controls were compared. The subjects were evaluated using the Adult ADHD Self-Report Scale, the Mini-International Neuropsychiatric Interview - short version, and the Wechsler Intelligence Scale. DNA samples were genotyped for the DAT1 3′ VNTR. Results: Logistic regression analysis was performed to compare the frequency of the 10.10 genotype (the putative risk genotype) to those of other genotypes. A significant difference (p = 0.04, OR = 1.758, CI = 1.026-3.012) indicating an increased frequency of the 10.10 genotype in the cases (59.9%) compared to the controls (49.3%) was verified using clinical and demographic covariates. Conclusions: This is one of the first genetic association studies on crack cocaine users in the literature. The results suggest an influence of the DAT1 gene, namely the 3′ VNTR 10.10 genotype. However, more analyses will confirm and clarify its contribution as a possible risk factor for crack cocaine dependence.

Keywords:
Crack cocaine, Dopamine transporter, DAT1 gene, Genetics, Addiction, Cocaine, Genetic polymorphism
1.
Bastos FI, Mendes A, Duarte PoC, Bertoni N: Smoked crack cocaine in contemporary Brazil: the emergence and spread of ‘oxi'. Addiction 2011;106:1191-1192.
2.
Abdalla RR, Madruga CS, Ribeiro M, Pinsky I, Caetano R, Laranjeira R: Prevalence of cocaine use in Brazil: data from the II Brazilian National Alcohol and Drugs Survey (BNADS). Addict Behav 2014;39:297-301.
3.
Reboussin BA, Anthony JC: Is there epidemiological evidence to support the idea that a cocaine dependence syndrome emerges soon after onset of cocaine use? Neuropsychopharmacology 2006;31:2055-2064.
4.
O'Brien MS, Anthony JC: Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000-2001. Neuropsychopharmacology 2005;30:1006-1018.
5.
SAMHSA: Results from the 2011 national survey on drug use and health: summary of national findings, 2011, 2013.
6.
Carlini EA, Galduróz JC, Noto AR, Carlini CM, Oliveira LG, Nappo SA, Moura YG, Sanchez ZVDM: Ii levantamento domiciliar sobre o uso de drogas psicotrópicas no Brasil: estudo envolvendo as 108 maiores cidades do país: 2005: CEBRID - Centro Brasileiro de Informações Sobre Drogas Psicotrópicas: UNIFESP - Universidade Federal de São Paulo. São Paulo, Páginas & Letras, 2007, pp 1-472.
7.
Volkow ND, Muenke M: The genetics of addiction. Hum Genet 2012;131:773-777.
8.
Volkow N, Li TK: The neuroscience of addiction. Nat Neurosci 2005;8:1429-1430.
9.
Schultz W: Dopamine signals for reward value and risk: basic and recent data. Behav Brain Funct 2010;6:24.
10.
Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F: Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA 2011;108:15037-15042.
11.
Lambert G, Karila L, Lowenstein W: Neuroimaging and cocaine: mapping dependence? Presse Med 2008;37:679-688.
12.
Gatley S, Volkow N, Wang G, Fowler J, Logan J, Ding Y, Gerasimov M: Pet imaging in clinical drug abuse research. Curr Pharm Des 2005;11:3203-3219.
13.
Shumay E, Chen J, Fowler JS, Volkow ND: Genotype and ancestry modulate brain's DAT availability in healthy humans. PLoS One 2011;6:e22754.
14.
Mroziewicz M, Tyndale RF: Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract 2010;5:17-29.
15.
Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S: The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 2001;1:152-156.
16.
Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR: Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992;14:1104-1106.
17.
van Dyck C, Malison R, Jacobsen L, Seibyl J, Staley J, Laruelle M, Baldwin R, Innis R, Gelernter J: Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med 2005;46:745-751.
18.
Fernàndez-Castillo N, Ribasés M, Roncero C, Casas M, Gonzalvo B, Cormand B: Association study between the DAT1, DBH and DRD2 genes and cocaine dependence in a Spanish sample. Psychiatr Genet 2010;20:317-320.
19.
Ballon N, Leroy S, Roy C, Bourdel MC, Olie JP, Charles-Nicolas A, Krebs MO, Poirier MF: Polymorphisms Taqi A of the DRD2, Bali of the DRD3, exon III repeat of the DRD4, and 3′ UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents? Am J Med Genet B Neuropsychiatr Genet 2007;144B:1034-1041.
20.
Lohoff FW, Bloch PJ, Hodge R, Nall AH, Ferraro TN, Kampman KM, Dackis CA, O'Brien CP, Pettinati HM, Oslin DW: Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence. Neurosci Lett 2010;473:87-91.
21.
Brousse G, Vorspan F, Ksouda K, Bloch V, Peoc'h K, Laplanche JL, Mouly S, Schmidt J, Llorca PM, Lepine JP: Could the inter-individual variability in cocaine-induced psychotic effects influence the development of cocaine addiction? Towards a new pharmacogenetic approach to addictions. Med Hypotheses 2010;75:600-604.
22.
Gelernter J, Kranzler HR, Satel SL, Rao PA: Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology 1994;11:195-200.
23.
Smith M, Thirthalli J, Abdallah A, Murray R, Cottler L: Prevalence of psychotic symptoms in substance users: a comparison across substances. Compr Psychiatry 2009;50:245-250.
24.
Haasen C, Prinzleve M, Gossop M, Fischer G, Casas M: Relationship between cocaine use and mental health problems in a sample of European cocaine powder or crack users. World Psychiatry 2005;4:173-176.
25.
Isaza C, Henao J, Beltrán L, Porras L, Gonzalez M, Cruz R, Carracedo A: Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine. Colomb Med (Cali) 2013;44:19-25.
26.
Vandenbergh DJ, Thompson MD, Cook EH, Bendahhou E, Nguyen T, Krasowski MD, Zarrabian D, Comings D, Sellers EM, Tyndale RF, George SR, O'Dowd BF, Uhl GR: Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Mol Psychiatry 2000;5:283-292.
27.
Guindalini C, Howard M, Haddley K, Laranjeira R, Collier D, Ammar N, Craig I, O'Gara C, Bubb VJ, Greenwood T, Kelsoe J, Asherson P, Murray RM, Castelo A, Quinn JP, Vallada H, Breen G: A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci USA 2006;103:4552-4557.
28.
APA: DSM IV-TR: manual diagnóstico e estatístico dos transtornos mentais, ed 4. Porto Alegre, Artes Médicas, 2002.
29.
Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33, quiz 34-57.
30.
Amorim P: Mini-International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr 2000;22:106-115.
31.
von Diemen L, Bassani D, Fuchs S, Szobot C, Pechansky F: Impulsivity, age of first alcohol use and substance use disorders among male adolescents: a population-based case-control study. Addiction 2008;103:1198-1205.
32.
Szobot C, Rohde L, Bukstein O, Molina B, Martins C, Ruaro P, Pechansky F: Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction 2007;102:1122-1130.
33.
Kessler FHP, Cacciola J, Faller S, Formigoni ML, Cruz MS, Brasiliano S, Pechansky F: Multi-center transcultural adaptation of the sixth version of Addiction Severity Index (ASI-6) for Brazil. Rev Psiquiatr 2007;29:335-336.
34.
McLellan A, Luborsky L, Woody G, O'Brien C: An improved diagnostic evaluation instrument for substance abuse patients. The addiction severity index. J Nerv Ment Dis 1980;168:26-33.
35.
Wechsler D: Wechsler abbreviated scale of intelligence manual. San Antonio, Psychological Corp, 1999.
36.
Mattos P, Segenreich D, Saboya E, Louzâ M, Dias G, Romano M: Transcultural adaptation of the adult self-report scale into Portuguese for evaluation of adult attention-deficit/hyperactivity disorder (ADHD). Rev Psiquiatr 2006;33:188-194.
37.
WHO: The Alcohol, Smoking and Substance Involvement Screening test (ASSIST): development, reliability and feasibility. Addiction 2002;97:1183-1194.
38.
Henrique I, De Micheli D, Lacerda R, Lacerda L, Formigoni M: Validation of the Brazilian version of Alcohol, Smoking and Substance Involvement Screening test (ASSIST). Rev Assoc Med Bras 2004;50:199-206.
39.
Lahiri D, Nurnberger JJ: A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19:5444.
40.
Sano A, Kondoh K, Kakimoto Y, Kondo I: A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 1993;91:405-406.
41.
Volkow ND, Wang GJ, Fowler JS, Tomasi D: Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 2012;52:321-336.
42.
Agrawal A, Verweij KJ, Gillespie NA, Heath AC, Lessov-Schlaggar CN, Martin NG, Nelson EC, Slutske WS, Whitfield JB, Lynskey MT: The genetics of addiction - a translational perspective. Transl Psychiatry 2012;2:e140.
43.
Gizer IR, Ficks C, Waldman ID: Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 2009;126:51-90.
44.
Sanchez-Mora C, Ribases M, Mulas F, Soutullo C, Sans A, Pamias M, Casas M, Ramos-Quiroga JA: Genetic bases of attention deficit hyperactivity disorder. Rev Neurol 2012;55:609-618.
45.
Biederman J, Petty CR, Ten Haagen KS, Small J, Doyle AE, Spencer T, Mick E, Monuteaux MC, Smoller JW, Faraone SV: Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder. Psychiatry Res 2009;170:199-203.
46.
Franke B, Hoogman M, Arias Vasquez A, Heister JG, Savelkoul PJ, Naber M, Scheffer H, Kiemeney LA, Kan CC, Kooij JJ, Buitelaar JK: Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD. Am J Med Genet B Neuropsychiatr Genet 2008;147B:1576-1579.
47.
El-Tarras AE, Alsulaimani AA, Awad NS, Mitwaly N, Said MM, Sabry AM: Association study between the dopamine-related candidate gene polymorphisms and ADHD among Saudi Arabia population via PCR technique. Mol Biol Rep 2012;39:11081-11086.
48.
Hutchison KE, Stallings M, McGeary J, Bryan A: Population stratification in the candidate gene study: fatal threat or red herring? Psychol Bull 2004;130:66-79.
49.
Durso DF, Bydlowski SP, Hutz MH, Suarez-Kurtz G, Magalhães TR, Pena SD: Association of genetic variants with self-assessed color categories in Brazilians. PLoS One 2014;9:e83926.
50.
Volkow ND, Skolnick P: New medications for substance use disorders: challenges and opportunities. Neuropsychopharmacology 2012;37:290-292.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.